Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bionano Genomics, Inc. (NASDAQ: BNGO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Bionano submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its financial condition, results of operations, risk factors and material corporate events.
Bionano’s recent Forms 8-K include disclosures about quarterly financial results, such as reports for the second and third quarters of 2025, and about capital markets transactions, including a September 2025 public offering of common stock and Series E and Series F warrants. The company has also filed a registration statement on Form S-1 relating to offerings of common stock, pre-funded warrants and warrants, which outlines offering terms, risk factors and use of proceeds.
Through this page, users can review Bionano’s descriptions of its business as a provider of optical genome mapping (OGM) solutions, diagnostic services and software, as well as its discussion of revenue sources, cost structure and liquidity. Filings may also include information on shareholder votes, such as the corrected voting results reported in an 8-K/A filed in June 2025, and details of securities purchase agreements and engagement letters with placement agents for public offerings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify topics such as OGM adoption, consumables and software utilization, capital raises and going concern considerations. Investors can use this resource to track Bionano’s Forms 10-K and 10-Q for comprehensive financial statements, Forms 8-K for event-driven updates, and registration statements for securities offerings, while AI-generated insights assist in understanding the implications of each filing.
Bionano Genomics, Inc. filed a Form 8-K reporting that on August 14, 2025 it issued a press release containing its financial results for the quarter ended June 30, 2025. The filing states the full press release is attached as Exhibit 99.1 to the report and notes that, consistent with applicable SEC guidance, the press release and related information are furnished rather than "filed" and are therefore not subject to Section 18 liabilities or automatically incorporated by reference into other SEC filings. The 8-K also contains a standard forward-looking statements caution describing assumptions, risks (including financing needs and geopolitical and macroeconomic uncertainty) and the possibility that actual results may differ materially from expectations.
Bionano Genomics (NASDAQ: BNGO) has filed an 8-K/A to amend its previous filing from June 13, 2025, correcting voting results for two key proposals. The amendment specifically addresses errors in reporting Broker Non-Votes and Votes For on Proposals 3 and 4.
Key Corrections:
- Proposal 3 (Ratification of BDO USA as auditor): Corrected to show 0 Broker Non-Votes instead of previously reported 769,744
- Proposal 4 (Warrant Exercise Share Issuance): Updated to show 396,176 Votes For (previously 369,176) and 769,744 Broker Non-Votes (previously unreported)
The corrections do not affect the outcome of either vote. Proposal 4 approved the issuance of up to 661,374 shares of common stock related to warrant exercises from a January 3, 2025 securities purchase agreement with institutional investors, in compliance with Nasdaq Listing Rule 5635(d).